From: Renin Angiotensin system-modifying therapies are associated with improved pulmonary health
Infectious (N = 21,523) | Inflammatory (N = 50,449) | Structural (N = 42,615) | |
---|---|---|---|
ACE-I vs Control | |||
Model 1 (Initial Drug) | |||
HR | 0.886 | 0.924 | 0.865 |
95%CI | 0.859–0.886 | 0.906–0.942 | 0.847–0.885 |
p | <0.0001 | <0.0001 | <0.0001 |
NNT | 240 | 156 | 104 |
Model 2 (Drug duration) | |||
Est | −0.0041 | −0.0034 | −0.031 |
p | <0.0001 | <0.0001 | <0.0001 |
ARB vs Control | |||
Model 1 (Initial Drug) | |||
HR | 0.957 | 0.970 | 0.900 |
95%CI | 0.914–1.009 | 0.940–1.001 | 0.868–0.933 |
p | 0.1067 | 0.0568 | <0.0001 |
NNT | 637 | 395 | 140 |
Model 2 (Drug duration) | |||
Est | −0.0050 | −0.0033 | −0.036 |
p | <0.0001 | <0.0001 | <0.0001 |